Compositions containing egg yolk powder and a NAD+ precursor and/or pterostilbene and/or an agent promoting mitochondrial rejuvenation for use in enhancing overall health and longevity in mammals are provided.

Compositions containing egg yolk powder and a NAD+ precursor and/or pterostilbene and/or an agent promoting mitochondrial rejuvenation for use in enhancing overall health and longevity in mammals are provided.

The present invention provides compositions comprising an active agent combination consisting of at least two of a cannabinoid, e.g., CBD, Dragon's blood, and palmitoylethanolamide (PEA), which is useful for treatment of inter alia inflammatory diseases or conditions of the skin; and methods of use.

The present invention provides compositions comprising an active agent combination consisting of at least two of a cannabinoid, e.g., CBD, Dragon's blood, and palmitoylethanolamide (PEA), which is useful for treatment of inter alia inflammatory diseases or conditions of the skin; and methods of use.

The pharmaceutical composition for treating dementia, comprising a mephenesin analogue compound and/or a compound with a carbamate structure. A therapeutic drug that can fundamentally treat dementia without causing side effects, such as an increase/decrease in body weight, loss of appetite, sexual debility, and symptoms of withdrawal can be provided with the pharmaceutical composition defined in the present invention. Combining this pharmaceutical composition with other pharmaceutical compositions, including cholinesterase inhibitors, can provide the most certain treatment method according to the symptoms.

The pharmaceutical composition for treating dementia, comprising a mephenesin analogue compound and/or a compound with a carbamate structure. A therapeutic drug that can fundamentally treat dementia without causing side effects, such as an increase/decrease in body weight, loss of appetite, sexual debility, and symptoms of withdrawal can be provided with the pharmaceutical composition defined in the present invention. Combining this pharmaceutical composition with other pharmaceutical compositions, including cholinesterase inhibitors, can provide the most certain treatment method according to the symptoms.

Various aspects of this patent document relate to compositions that comprise an anion that is the conjugate base of a hydrophobic molecule that has a pKa, for example, of at least 7 and no greater than 12. These compositions display improved properties when formulated to interact with an organism because the anions carry negative charges that allows them to both dissolve in water-miscible liquids and maximize their surface area. Interaction with an organism results in at least partial conversion of the anion into the hydrophobic molecule after which the hydrophobic molecule partitions out of a water-miscible liquid and into the organism.

This invention relates to oral care compositions comprising herbal extracts including, e.g., Gymnema sylvestre, Emblica officinalis, Eugenia jambolana, Azadirachta indica, and combinations thereof and zinc salts, e.g., zinc citrate and zinc oxide. Additionally, the invention relates to methods of using and of making these compositions, e.g., method of using the oral care compositions to treat gingivitis in diabetic consumers.

This invention relates to oral care compositions comprising herbal extracts including, e.g., Gymnema sylvestre, Emblica officinalis, Eugenia jambolana, Azadirachta indica, and combinations thereof and zinc salts, e.g., zinc citrate and zinc oxide. Additionally, the invention relates to methods of using and of making these compositions, e.g., method of using the oral care compositions to treat gingivitis in diabetic consumers.

The present invention relates to a compound having general formula I for use in the activation of AMPK. A composition comprising said compound for use in the activation of AMPK is also provided. Said compounds are 9,10 dihydrophenanthrenes, in particular selected from the group consisting of: (i) Lusianthridin i.e. 7-Methoxy-9,10-dihydrophenanthrene-2,5-diol, (ii) 7-Methoxy-9,10-dihydrophenanthrene-2,3,5-triol, (iii) 9,10-dihydrophenanthrene-2,5-diol, (iv) 9,10-Dihydrophenanthrene-2,4,7-triol (v) 9,10-Dihydro-7-methoxy-3,5-phenanthrenediol, and the activation of AMPK improves the condition, disorder, or disease related to cardiometabolic health, obesity, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, and cancer.